(+)-.Beta.-L-Carbocyclic thymidine (CAS 192118-46-0)
(+)-.Beta.-L-Carbocyclic thymidine (CAS:
192118-46-0) has molecular formula C11H16N2O5 and molecular weight 256.25 g/mol. This compound has been the subject of numerous scientific investigations due to its structural features and practical utility in synthetic chemistry and industrial processes. View product details →
Product Background
This comprehensive research profile examines the scientific literature surrounding (+)-.Beta.-L-Carbocyclic thymidine.
Key Research Findings
- Nucleoside supplementation has been shown to favorably alter the disease's course, particularly in severe infantile-onset cases.
- Zolbetuximab is an anti-claudin18.2 antibody, and the addition of zolbetuximab in combination with fluoropyrimidine and oxaliplatin as a first-line treatment for CLDN18.2-positi
- The results demonstrated that consecutive centrifugal washing cycles significantly reduced residue levels in porcine cultured meat biomass, with the majority of the 12 target sub
Detailed Literature Analysis
Below are the top-ranked research papers for (+)-.Beta.-L-Carbocyclic thymidine, presented with bibliographic details and scientific abstracts.
Biological & Pharmacological Studies
1. Nucleoside therapy for thymidine kinase 2 deficiency: Long-term outcomes from a Brazilian cohort.
BackgroundThymidine Kinase 2 deficiency (TK2d) is a rare, mitochondrial DNA (mtDNA) depletion/deletions syndrome leading to a severe and progressive myopathic disorder. Nucleoside supplementation (deoxythymidine and deoxycytidine) has been shown to favorably alter the disease's course, particularly in severe infantile-onset cases. Long-term dat
🔑 Key Finding: Nucleoside supplementation has been shown to favorably alter the disease's course, particularly in severe infantile-onset cases.
Other Research
2. Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study P
Zolbetuximab is an anti-claudin18.2 (CLDN18.2) antibody, and the addition of zolbetuximab in combination with fluoropyrimidine and oxaliplatin as a first-line treatment for CLDN18.2-positive and HER2-negative gastric or gastroesophageal junction adenocarcinoma has been shown to improve survival. However, the efficacy and safety of the combinati
3. Determination of multiple risk substances in porcine cultured meat biomass and washing solutions using LC-MS/MS: method development, validation, and risk assessment.
Cultured meat presents significant potential as a sustainable supplement to traditional livestock farming. Addressing the critical challenge of residual chemical substances from the culture media, this study established a rapid method combining protein precipitation (PP) with liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the qua
Conclusion
The research literature on (+)-.Beta.-L-Carbocyclic thymidine demonstrates sustained scientific interest, with publications continuing through 0. The compound serves as an important building block in synthetic chemistry and has been explored for various applications. Researchers and industrial users can view detailed specifications or submit an inquiry for pricing and availability.
Data Sources: PubMed/MEDLINE, CrossRef. 3 papers analyzed. Last updated: 2026-05-25. This article is automatically generated from peer-reviewed research data.